|
|
Upfront Briefing
Biohaven agreed to license opakalim to SK Biopharmaceuticals for up to $795M two weeks ago. On Thursday it disclosed an FDA partial hold on the same drug over a rodent metabolite. Awkward timing, softer fine print: the fully enrolled RISE-3 still reads out this year, and Biohaven says SK saw the data before signing. Novartis now has a shareholder problem to match its pipeline problem, with Artisan Partners calling for a board shake-up over deal oversight. AbbVie had the calmer day, landing a Phase 3 win in menstrual migraine. WCLC opens in Seoul tomorrow and Morgan Stanley's healthcare conference starts Monday, so the weekend is shorter than it looks.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,591.7 |
(0.6%) |
10.7% |
| Nasdaq 100 |
29,103.5 |
(1.1%) |
15.5% |
| Russell 2000 |
2,890.9 |
(1.0%) |
15.3% |
| Healthcare (XLV) |
165.7 |
(0.6%) |
6.5% |
| Biotech (XBI) |
156.8 |
(1.6%) |
29.0% |
| Nasdaq Biotech (NBI) |
6,921.2 |
(1.4%) |
21.3% |
| Clinical Trials (BBC) |
49.9 |
(2.9%) |
32.6% |
|
- Biotech underperformed a weak tape, with XBI down 1.6% and NBI down 1.4% against 0.6% declines for both XLV and the S&P 500; the clinical-stage BBC basket fell 2.9%. Biohaven, which disclosed its FDA partial hold before the open, closed down more than 10%.
- Oil set the macro tone: WTI settled up 6.7% at $102.48 and Brent at $107.63, both the highest closes since 19 May, as the Iran war kept crude flows constrained. August PPI rose 0.4% month on month, the 10-year yield climbed to 4.95%, and traders priced roughly 70% odds of a Fed hike next week ahead of Friday's CPI, leaving the S&P 500 with a fourth straight loss.
- Market data: U.S. cash close Thursday, 10 September 2026.
The Big 3
|
1
|
Biohaven's SK-partnered epilepsy drug hits an FDA partial hold
|
- Biohaven disclosed in an SEC filing that FDA placed a partial clinical hold on opakalim (BHV-7000), its Kv7.2/7.3 activator in focal epilepsy, pausing new enrollment until further nonclinical studies characterise a metabolite seen in rodents.
- Why it matters: The hold hits an asset Biohaven agreed on 26 August to license to SK Biopharmaceuticals for up to $795M, and that deal is still pending, with $350M due at closing. Dosing continues for the 600-plus patients already randomised, and RISE-3, one of two pivotal focal-epilepsy studies, is fully enrolled with topline still guided for H2 2026. The exposure is RISE-2, where enrollment is now frozen; RBC flagged that readout as potentially necessary for approval. Biohaven says SK saw all the metabolite data before signing, and Baird called such holds fairly common and quickly resolvable. Xenon's rival Kv7 opener azetukalner is heading for an NDA in Q3, so any delay widens its lead. BHVN fell more than 10% on its second regulatory setback in a year, after the troriluzole CRL.
- Source: Endpoints
- More: BioPharma Dive; Fierce Biotech
|
|
2
|
Novartis holder Artisan demands a board shake-up after deal misfires
|
- Artisan Partners' David Samra, whose firm ranks among Novartis' 20 largest shareholders, told Reuters that chair Giovanni Caforio needs to make board-level changes and fix how deals are overseen, after back-to-back Phase 3 failures for pelacarsen and the Avidity-acquired del-desiran.
- Why it matters: Artisan is the first holder to go public, but Reuters followed up with eight shareholders questioning the $12B Avidity purchase and other acquisitions, so the pressure is broader than one fund. Artisan still backs CEO Vas Narasimhan, which makes new board seats and tighter deal oversight a likelier outcome than a management change. The del-desiran miss took about 11% off the shares in a single session, roughly $30B of value and the year's gains. Novartis says sales guidance before and after 2030 is unchanged, and it can point to remibrutinib's MS wins and the $3.22B Alteogen licence. A board under this much scrutiny is likely to push future deals toward milestones over upfront cash, which matters to anyone pitching it an asset.
- Source: Fierce Biotech
- More: Reuters; BioSpace
|
| 3 | AbbVie's Qulipta wins Phase 3 in menstrual migraine |
- Atogepant met its primary endpoint and all eight ranked secondary endpoints in the 468-patient Phase 3 LUNA trial, taken for seven days starting three days before menses across three cycles.
- Why it matters: Perimenstrual migraine days fell by 1.20 on atogepant against 0.40 on placebo, a 0.80-day gap at p<0.0001, with no new safety signal. The absolute benefit is under a day per cycle, so the commercial case rests on dosing: a short, predictable course instead of daily prevention, in a condition with no drug approved specifically for it. AbbVie says LUNA is the first positive Phase 3 for a CGRP-targeted drug in the indication, which would give Qulipta a label claim no CGRP rival carries. LUNA enrolled only in Europe and Asia, so US regulators may test whether the data carry over. AbbVie plans global filings but gave no timing, and full data are held for a future congress.
- Source: Fierce Pharma
- More: NeurologyLive
|
Everything Else that broke
- BridgeBio Oncology fell 24% after narrowing BBO-8520 to second-line-plus KRAS G12C lung cancer and trimming its broader KRAS pipeline plans. — Endpoints
- Shionogi's redasemtide, licensed from StemRIM, missed the primary endpoint of its global Phase 2b REvive trial in acute ischemic stroke, though a separate Phase 2 in dystrophic epidermolysis bullosa was positive. — Endpoints
- Frazier Life Sciences closed more than $1.1B in oversubscribed commitments to its evergreen Public Fund for small- and mid-cap biotechs, taking the vehicle to about $2.8B raised since 2021. — Fierce Biotech
- NICE draft guidance declined to recommend Gilead's twice-yearly lenacapavir injection for routine NHS use as HIV prevention. — Fierce Pharma
- FDA signaled flexibility on psychedelic trial comparators beyond placebo. — Endpoints
- Takeda's long-serving R&D president Andy Plump will retire, leaving the company in June 2027. — Fierce Biotech
- Samsung Biologics signed a $262M manufacturing contract with an unnamed European pharma while it waits to break into peptides. — Fierce Pharma
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- EMD Serono acquired PostEra's preclinical FSHR and LHCGR small-molecule agonist fertility programmes, both built on PostEra's Proton AI platform; no financial terms were disclosed. — PR Newswire
VC / Private Financings
- CONNECTA Therapeutics closed a €3.1M financing to advance CTH120 in Fragile X syndrome, led by Clave Capital with backing from Inveready, CDTI Innvierte and Prous Institute for Biomedical Research. — GlobeNewswire
IPOs / Follow-Ons
- No notable IPOs / follow-ons in the last 24 hours.
Academic Corner - Mitapivat significantly reduced transfusion burden in adults with transfusion-dependent α-thalassaemia or β-thalassaemia in the phase 3 ENERGIZE-T trial. — Lancet
- An editorial examined how gene-editing therapies can be delivered safely for patients as approvals broaden. — Lancet
|
|
Have a good weekend, and may your enrollment stay unpaused.
— BioBucks Team
|
|
|
